American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain
Top Cited Papers
Open Access
- 19 June 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (12), 2656-2701
- https://doi.org/10.1182/bloodadvances.2020001851
Abstract
The management of acute and chronic pain for individuals living with sickle cell disease (SCD) is a clinical challenge. This reflects the paucity of clinical SCD pain research and limited understanding of the complex biological differences between acute and chronic pain. These issues collectively create barriers to effective, targeted interventions. Optimal pain management requires interdisciplinary care. These evidence-based guidelines developed by the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in pain management decisions for children and adults with SCD. ASH formed a multidisciplinary panel, including 2 patient representatives, that was thoroughly vetted to minimize bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including updating or performing systematic reviews. Clinical questions and outcomes were prioritized according to importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. The panel reached consensus on 18 recommendations specific to acute and chronic pain. The recommendations reflect a broad pain management approach, encompassing pharmacological and nonpharmacological interventions and analgesic delivery. Because of low-certainty evidence and closely balanced benefits and harms, most recommendations are conditional. Patient preferences should drive clinical decisions. Policymaking, including that by payers, will require substantial debate and input from stakeholders. Randomized controlled trials and comparative-effectiveness studies are needed for chronic opioid therapy, nonopioid therapies, and nonpharmacological interventions.Keywords
This publication has 170 references indexed in Scilit:
- IMPROVE trial: A randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studiesClinical Trials, 2013
- A Family-based Randomized Controlled Trial of Pain Intervention for Adolescents With Sickle Cell DiseaseJournal of Pediatric Hematology/Oncology, 2010
- Emergency Department Sickle Cell Assessment of Needs and Strengths (ED‐SCANS), a Focus Group and Decision Support Tool Development ProjectAcademic Emergency Medicine, 2010
- A systematic review on the effectiveness of physical and rehabilitation interventions for chronic non-specific low back painEuropean Spine Journal, 2010
- The Vexing Problem of Guidelines and Conflict of Interest: A Potential SolutionAnnals of Internal Medicine, 2010
- A systematic review on the effectiveness of complementary and alternative medicine for chronic non-specific low-back painEuropean Spine Journal, 2010
- Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trialsArthritis Research & Therapy, 2009
- Motor Control Exercise for Persistent, Nonspecific Low Back Pain: A Systematic ReviewPTJ: Physical Therapy & Rehabilitation Journal, 2009
- Effects of a long-term transfusion regimen on sickle cell-related illnessesThe Journal of Pediatrics, 1994
- Analgesic use in the emergency departmentAnnals of Emergency Medicine, 1990